United Therapeutics Corp (NASDAQ: UTHR), which has an office in the Research Triangle, has received approval of a new inhalation device from the U.S. Food and Drug Administration (FDA) for use with its drug Tyvaso. Tyvaso, has been the focal point of a number of patent disputes. A treatment for pulmonary hypertension (PAH), the drug generates significant sales for the company.